Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBIENCE trial of zenagamtide for cardiovascular risk reduction in overweight or obese adults with established atherosclerotic cardiovascular disease
2026-525182-53-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Oct 2026
- Modality
- Small Molecules, Peptides
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease, Overweight and obesity comparing Zenagamtide with Placebo (2 arms). Primary endpoint: 4-point major adverse cardiovascular events. Planned start Oct 2026; status: authorised.
02
Drugs
amycretin
03
Conditions
atherosclerotic diseaseOverweightobesity
Beyond the preview
Go deeper on 2026-525182-53-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525182-53-00.